Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 10
- Registration Number
- NCT06355024
DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT06354231
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 10
- Registration Number
- NCT06355037
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
Pilot Study of Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in China
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 24
- Registration Number
- NCT06355440
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer
Recruiting
- Conditions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1263
- Registration Number
- NCT06349252
- Locations
- 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarcinoma
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 5302
- Registration Number
- NCT06344299
- Locations
- 🇨🇳
Huadong Hospital affiliated to Fudan University, Shanghai, China
Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor
Completed
- Conditions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 19
- Registration Number
- NCT06344767
- Locations
- 🇨🇳
China,Shanghai, Shanghai, Shanghai, China
Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
Active, not recruiting
- Conditions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT06344780
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
Active, not recruiting
- Conditions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT06344793
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1900
- Registration Number
- NCT06341621
- Locations
- 🇨🇳
Zhimin Cancer Shao, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath